US · TRIB
Trinity Biotech plc
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Bray A98 H5C8
- Website
- trinitybiotech.com
Price · as of 2024-12-31
$0.61
Market cap 7.47M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $50.26 | +8,173.25% |
| Intrinsic Value(DCF) | $0.28 | -53.91% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $43.60 | $86.08 | $6.06 | $100.44 | $0.00 |
| 2011 | $49.90 | $142.37 | $15.08 | $41.66 | $0.00 |
| 2012 | $90.27 | $143.76 | $17.32 | $42.25 | $55.37 |
| 2013 | $136.06 | $228.19 | $9.38 | $26.41 | $43.05 |
| 2014 | $91.91 | $97.65 | $0.00 | $33.95 | $85.04 |
| 2015 | $56.60 | $111.83 | $12.35 | $41.81 | $18.45 |
| 2016 | $28.40 | $52.91 | $5.37 | $0.00 | $0.00 |
| 2017 | $28.65 | $90.67 | $4.80 | $0.00 | $0.00 |
| 2018 | $14.75 | $167.65 | $0.00 | $9.54 | $3.44 |
| 2019 | $7.00 | $108.87 | $0.00 | $0.00 | $0.00 |
| 2020 | $23.05 | $62.58 | $0.00 | $0.00 | $0.00 |
| 2021 | $5.00 | $144.04 | $0.00 | $0.00 | $0.00 |
| 2022 | $4.85 | $987.08 | $0.00 | $0.00 | $84.29 |
| 2023 | $2.23 | $81.69 | $0.00 | $0.00 | $1.50 |
| 2024 | $0.69 | $50.26 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Trinity Biotech plc's (TRIB) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $50.26
- Current price
- $0.61
- AI upside
- +8,173.25%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.28
-53.91% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| TRIB | Trinity Biotech plc | $0.61 | 7.47M | +8,173% | -54% | — | — | -0.39 | -0.35 | 0.20 | -6.39 | — | -0.14 | 34.83% | -34.38% | -51.64% | 107.52% | -42.24% | -39.07% | -2.86 | -2.21 | 1.28 | 0.62 | -5.65 | -4469.00% | 831.00% | 1533.00% | -115.03% | -0.13 | -28.45% | 0.00% | 0.00% | 0.00% | -5.10 | -7.58 | 1.75 | -0.99 |
| ADVB | Advanced Biomed Inc. Comm… | $4.06 | 4.4M | — | — | — | — | -1690.19 | 0.05 | — | — | -7324.16 | 0.05 | 0.00% | — | — | -0.01% | 0.00% | 0.00% | 0.00 | — | 2.09 | 1.01 | — | 2308.00% | — | -9171.00% | -0.11% | 0.00 | -0.06% | 0.00% | 0.00% | 1690.13% | — | 14968.87 | — | -3.52 |
| BGLC | BioNexus Gene Lab Corp. | $2.72 | 4.89M | +1,907% | +316% | -93% | — | -4.11 | 0.79 | 0.69 | -1.70 | — | 0.79 | 13.56% | -16.55% | -16.81% | -17.78% | -39.19% | -14.64% | 0.03 | -74.42 | 3.81 | 3.05 | 2.93 | -4118.00% | -266.00% | 2885.00% | -37.43% | -1.15 | -61.29% | 0.00% | 0.00% | 0.00% | -1.53 | -0.98 | 0.25 | 2.45 |
| CHEK | Check-Cap Ltd. | $1.68 | 9.83M | — | — | — | — | -0.19 | -3.24 | — | -0.49 | -0.43 | -3.24 | 0.00% | — | — | -226.19% | 1959.89% | -198.07% | -0.09 | -2883.22 | 0.15 | 0.15 | -0.01 | 4333.00% | — | -9995.00% | -0.17% | 0.00 | 0.60% | 0.00% | 0.00% | 0.00% | -0.18 | -570.68 | — | -861.86 |
| EVGN | Evogene Ltd. | $0.88 | 7.65M | +2,548% | -33% | — | — | -0.47 | -5.81 | 0.99 | -0.39 | — | -0.62 | 39.81% | -255.36% | -193.69% | -340.58% | 381.57% | -39.69% | -8.87 | -175.27 | 1.15 | 0.90 | 0.16 | -4474.00% | 5090.00% | -910.00% | -241.06% | -1.05 | 356.85% | 0.00% | 0.00% | 0.00% | -0.28 | -0.29 | 0.70 | -10.92 |
| MRKR | Marker Therapeutics, Inc. | $1.48 | 15.98M | +3,230% | -2% | — | — | -1.26 | 0.73 | 2.04 | 0.51 | — | 0.73 | -104.33% | -168.69% | -162.82% | -65.81% | 1313.50% | -54.82% | 0.00 | — | 6.36 | 6.22 | 1.73 | -3834.00% | 9906.00% | -3364.00% | -81.00% | -3.15 | 1288.92% | 0.00% | 0.00% | 30.30% | 0.51 | 0.52 | -0.87 | -26.44 |
| SINT | Sintx Technologies, Inc. | $2.89 | 7.97M | +19,466% | -54% | — | +21,505% | -0.22 | 0.63 | 1.98 | -0.30 | — | 0.64 | 34.91% | -1127.37% | -884.75% | -174.07% | -193.62% | -88.98% | 1.03 | -484.38 | 2.41 | 1.91 | -0.04 | -2178.00% | -5257.00% | -3628.00% | -378.55% | -4.36 | -128.63% | 0.00% | 0.00% | 40.16% | -0.21 | -0.31 | 2.32 | -46.07 |
| SNSE | Sensei Biotherapeutics, I… | $30.50 | 38.48M | — | — | — | — | -7.50 | 5.89 | — | -6.39 | — | 5.89 | 0.00% | — | — | -58.40% | -1014.51% | -50.37% | 0.10 | -351.81 | 7.70 | 7.59 | 0.21 | -164.00% | — | -2294.00% | -10.98% | -4.53 | -795.13% | 0.00% | 0.00% | 0.00% | -5.96 | -7.60 | — | 10.02 |
| TNON | Tenon Medical, Inc. | $0.87 | 7.5M | +21,018% | +210,838% | — | — | -0.12 | 0.26 | 0.48 | 0.35 | — | 0.26 | 52.21% | -420.08% | -417.24% | -405.19% | -38777.46% | -168.93% | 0.07 | -404.88 | 4.39 | 3.96 | 0.47 | -8360.00% | 1192.00% | -1977.00% | -637.69% | -5.29 | -28349.30% | 0.00% | 0.00% | 350.78% | 0.33 | 0.45 | -1.38 | -13.04 |
| XAIR | Beyond Air, Inc. | $0.96 | 4.87M | +6,086% | +58% | — | — | -0.27 | 0.95 | 3.47 | -0.42 | — | 1.04 | -44.89% | -1202.08% | -1258.43% | -250.98% | -332.73% | -111.42% | 0.86 | -14.75 | 3.20 | 1.56 | -0.17 | -6210.00% | 21967.00% | -2859.00% | -342.82% | -7.64 | -329.47% | 0.00% | 0.00% | 0.00% | -0.40 | -0.40 | 4.76 | -17.17 |
About Trinity Biotech plc
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
- CEO
- John Gillard
- Employees
- 380
- Beta
- 0.60
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.28 ÷ $0.61) − 1 = -53.91% (DCF, example).